

environment as they relate to access to care for patients with acute cardiac ischemia. Attendance by the public will be limited to space available.

For detailed program information, agenda, list of participants, and meeting summary, contact: Ms. Mary Hand, Coordinator, National Heart Attack Alert Program, Office of Prevention, Education and Control; National Heart, Lung, and Blood Institute; National Institutes of Health, Building 31, Room 4A-18, 31 Center Drive MSC 2480, Bethesda, Maryland 20892-2480, (301) 496-1051.

Dated: October 23, 1995.

Claude Lenfant,

Director, NHLBI.

[FR Doc. 95-27174 Filed 11-1-95; 8:45 am]

BILLING CODE 4140-01-M

### National Institute of Mental Health; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Institute of Mental Health Initial Review Group, Mental Health AIDS and Immunology Review Committee, which was published in the Federal Register on September 1, 1995 (60 CFR 45728).

This committee was to have convened at 8:30 a.m. on November 7 at the One Washington Circle Hotel in Washington, D.C. The starting date has been changed to November 6.

Dated: October 30, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95-27256 Filed 11-1-95; 8:45 am]

BILLING CODE 4140-01-M

### Division of Research Grants; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

*Purpose/Agenda:* To review Small Business Innovation Research.

*Name of SEP:* Biological and Physiological Sciences.

*Date:* November 6, 1995.

*Time:* 8:30 a.m.

*Place:* American Inn of Bethesda, Bethesda, Maryland.

*Contact Person:* Dr. Abubakar A. Shaikh, Scientific Review Administrator, 6701 Rockledge Drive, Room 6166, Bethesda, Maryland 20892, (301) 435-1042.

*Purpose/Agenda:* To review individual grant applications.

*Name of SEP:* Biological and Physiological Sciences.

*Date:* November 17, 1995.

*Time:* 3:00 p.m.

*Place:* NIH, Rockledge 2, Room 6166, Telephone Conference.

*Contact Person:* Dr. Abubakar A. Shaikh, Scientific Review Administrator, 6701 Rockledge Drive, Room 6166, Bethesda, Maryland 20892, (301) 435-1042.

*Name of SEP:* Clinical Sciences.

*Date:* November 21, 1995.

*Time:* 10:30 a.m.

*Place:* Holiday Inn-Olde Town Alexandria, Alexandria, Virginia.

*Contact Person:* Dr. Priscilla B. Chen, Scientific Review Administrator, 6701 Rockledge Drive, Room 4104, Bethesda, Maryland 20892, (301) 435-1787.

*Name of SEP:* Microbiological and Immunological Sciences.

*Date:* December 6, 1995.

*Time:* 1:30 p.m.

*Place:* NIH, Rockledge 2, Room 4182, Telephone Conference.

*Contact Person:* Dr. William Branche, Jr., Scientific Review Administrator, 6701 Rockledge Drive, Room 4182, Bethesda, Maryland 20892, (301) 435-1148.

*Name of SEP:* Microbiological and Immunological Sciences.

*Date:* December 11, 1995.

*Time:* 1:30 p.m.

*Place:* NIH, Rockledge 2, Room 4182, Telephone Conference.

*Contact Person:* Dr. William Branche, Jr., Scientific Review Administrator, 6701 Rockledge Drive, Room 4182, Bethesda, Maryland 20892, (301) 435-1148.

The meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the grant review cycle.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393-93.396, 93.837-844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: October 30, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95-27254 Filed 11-1-95; 8:45 am]

BILLING CODE 4140-01-M

### Public Health Service

#### Health Resources and Services Administration; Statement of Organization, Functions and Delegations of Authority

Part H, Chapter HB (Health Resources and Services Administration) of the Statement of Organization, Functions and Delegations of Authority of the

Department of Health and Human Services (47 FR 38409-24, August 31, 1982, as amended most recently at 60 FR 48164, September 18, 1995 is amended to reflect the following changes in the Bureau of Health Resources Development:

1. Rename the Division of Organ Transplantation;
2. Abolish the Equal Employment Opportunity Staff in the Office of the Director; and
3. Revise the Immediate Office of the Director.

Under Section HB-20, Organization and Functions, amend the functional statements for the *Health Resources and Services Administration (HBB)* as follows:

1. Rename the *Division of Organ Transplantation (HBB3)*, to the Division of Transplantation. The functional statement is not changed.
2. Delete the *Equal Employment Opportunity Staff*, Office of the Director, functional statement in its entirety;
3. Delete the functional statement of the Office of the Director (HBB1) and enter the following:

Office of the Director (HBB1)

Provides leadership and direction for the programs and activities of the Bureau and oversees its relationship with other national health programs. Specifically: (1) Coordinates the internal functions of the Bureau and its relationships with other national health programs; (2) establishes program objectives, alternatives, and polity positions consistent with legislation and broad Administration guidelines; (3) develops and administers operating policies and procedures, and provides guidance and assistance to regional staff as appropriate; (4) evaluates program accomplishments; (5) serves as principal contact and advisor to the Department and other parties concerned with matters relating to planning and development of health delivery systems; (6) provides information about Bureau programs to the general public, health professions associations, and other interested groups and organizations; (7) directs and coordinates Bureau Executive Secretariat activities; (8) directs and coordinates the Bureau activities carried out in support of the Department/Bureau's Affirmative Action and Equal Employment Opportunity programs by ensuring that all internal employment practices provide an equal opportunity to all qualified persons and its employment practices do not discriminate on the basis of race, color, sex, national origin, religious affiliation, marital age or handicap status, and that all external

benefits and service oriented activities relative to the recipients of federal funds are likewise addressed in accordance with applicable laws, Executive Orders, DHHS regulations and policies; and (9) provides direction for the Bureau's Civil Rights compliance activities.

#### Delegations of Authority

All delegations and redelegations of authorities to offices and employees of the Health Resources and Services Administration which were in effect immediately prior to the effective date of this reorganization will be continued in effect in them or their successors, pending further redelegation, provided they are consistent with this reorganization.

#### Effective Date

This reorganization is effective upon date of signature.

Dated: October 28, 1995.

Ciro V. Sumaya,  
Administrator.

[FR Doc. 95-27190 Filed 11-1-95; 8:45 am]

BILLING CODE 4160-15-M

### Substance Abuse and Mental Health Services Administration

#### Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies and Laboratories That Have Withdrawn From the Program

**AGENCY:** Substance Abuse and Mental Health Services Administration, HHS (Formerly: National Institute on Drug Abuse, ADAMHA, HHS).

**ACTION:** Notice.

**SUMMARY:** The Department of Health and Human Services notifies Federal agencies of the laboratories currently certified to meet standards of Subpart C of Mandatory Guidelines for Federal Workplace Drug Testing Programs (59 FR 29916, 29925). A similar notice listing all currently certified laboratories will be published during the first week of each month, and updated to include laboratories which subsequently apply for and complete the certification process. If any listed laboratory's certification is totally suspended or revoked, the laboratory will be omitted from updated lists until such time as it is restored to full certification under the Guidelines.

If any laboratory has withdrawn from the National Laboratory Certification Program during the past month, it will be identified as such at the end of the current list of certified laboratories, and

will be omitted from the monthly listing thereafter.

**FOR FURTHER INFORMATION CONTACT:** Mrs. Giselle Hersh, Division of Workplace Programs, Room 13A-54, 5600 Fishers Lane, Rockville, Maryland 20857; Tel.: (301) 443-6014.

#### SUPPLEMENTARY INFORMATION:

Mandatory Guidelines for Federal Workplace Drug Testing were developed in accordance with Executive Order 12564 and section 503 of Public Law 100-71. Subpart C of the Guidelines, "Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies," sets strict standards which laboratories must meet in order to conduct urine drug testing for Federal agencies. To become certified an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification a laboratory must participate in a quarterly performance testing program plus periodic, on-site inspections.

Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements expressed in the HHS Guidelines. A laboratory must have its letter of certification from SAMHSA, HHS (formerly: HHS/NIDA) which attests that it has met minimum standards.

In accordance with Subpart C of the Guidelines, the following laboratories meet the minimum standards set forth in the Guidelines:

Aegis Analytical Laboratories, Inc., 624 Grassmere Park Rd., Suite 21, Nashville, TN 37211, 615-331-5300  
Alabama Reference Laboratories, Inc., 543 South Hull St., Montgomery, AL 36103, 800-541-4931/205-263-5745  
American Medical Laboratories, Inc., 14225 Newbrook Dr., Chantilly, VA 22021, 703-802-6900  
Associated Pathologists Laboratories, Inc., 4230 South Burnham Ave., Suite 250, Las Vegas, NV 89119-5412, 702-733-7866  
Associated Regional and University Pathologists, Inc. (ARUP), 500 Chipeta Way, Salt Lake City, UT 84108, 801-583-2787  
Baptist Medical Center—Toxicology Laboratory, 9601 I-630, Exit 7, Little Rock, AR 72205-7299, 501-227-2783 (Formerly: Forensic Toxicology Laboratory Baptist Medical Center)  
Bayshore Clinical Laboratory, 4555 W. Schroeder Dr., Brown Deer, WI 53223, 414-355-4444/800-877-7016  
Cedars Medical Center, Department of Pathology, 1400 Northwest 12th Ave., Miami, FL 33136, 305-325-5810  
Centinela Hospital Airport Toxicology Laboratory, 9601 S. Sepulveda Blvd.,

Los Angeles, CA 90045, 310-215-6020

Clinical Reference Lab, 11850 West 85th St., Lenexa, KS 66214, 800-445-6917  
CompuChem Laboratories, Inc., 3308 Chapel Hill/Nelson Hwy., Research Triangle Park, NC 27709, 919-549-8263/800-833-3984 (Formerly: CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory, Roche CompuChem Laboratories, Inc., A Member of the Roche Group)

CompuChem Laboratories, Inc., Special Division, 3308 Chapel Hill/Nelson Hwy., Research Triangle Park, NC 27709, 919-549-8263 (Formerly: Roche CompuChem Laboratories, Inc., Special Division, A Member of the Roche Group, CompuChem Laboratories, Inc.—Special Division)  
CORNING Clinical Laboratories, South Central Division, 2320 Schuetz Rd., St. Louis, MO 63146, 800-288-7293 (Formerly: Metropolitan Reference Laboratories, Inc.)

CORNING Clinical Laboratories, 8300 Esters Blvd., Suite 900, Irving, TX 75063, 800-526-0947 (Formerly: Damon Clinical Laboratories, Damon/MetPath)

CORNING Clinical Laboratories, 24451 Telegraph Rd., Southfield, MI 48034, 800-444-0106 ext. 650 (Formerly: HealthCare/Preferred Laboratories, HealthCare/MetPath)

CORNING Clinical Laboratories Inc., 1355 Mittel Blvd., Wood Dale, IL 60191, 708-595-3888 (Formerly: MetPath, Inc., CORNING MetPath Clinical Laboratories)

CORNING MetPath Clinical Laboratories, One Malcolm Ave., Teterboro, NJ 07608, 201-393-5000 (Formerly: MetPath, Inc.)

CORNING National Center for Forensic Science, 1901 Sulphur Spring Rd., Baltimore, MD 21227, 410-536-1485 (Formerly: Maryland Medical Laboratory, Inc., National Center for Forensic Science)

CORNING Nichols Institute, 7470-A Mission Valley Rd., San Diego, CA 92108-4406, 800-446-4728/619-686-3200 (Formerly: Nichols Institute, Nichols Institute Substance Abuse Testing (NISAT))

Cox Medical Centers, Department of Toxicology, 1423 North Jefferson Ave., Springfield, MO 65802, 800-876-3652/417-836-3093

Dept. of the Navy, Navy Drug Screening Laboratory, Great Lakes, IL, Building 38-H, Great Lakes, IL 60088-5223, 708-688-2045/708-688-4171

Diagnostic Services Inc., dba DSI, 4048 Evans Ave., Suite 301, Fort Myers, FL 33901, 813-936-5446/800-735-5416